CASALI, PAOLO GIOVANNI
CASALI, PAOLO GIOVANNI
Dipartimento di Oncologia ed Emato-Oncologia
(Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair
2017 M. Saponara, S. Stacchiotti, P.G. Casali, A. Gronchi
2018 ESMO Sarcoma and GIST Symposium: take-home messages' in soft tissue sarcoma
2018 A.M. Frezza, A.T.J. Lee, E. Nizri, M. Sbaraglia, R.L. Jones, A. Gronchi, A.P. Dei Tos, P.G. Casali
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
2004 E. Tamborini, L. Bonadiman, A. Greco, V. Albertini, T. Negri, A. Gronchi, R. Bertulli, M. Colecchia, P.G. Casali, M.A. Pierotti, S. Pilotti
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
2007 D. Mannavola, P. Coco, G. M. Vannucchi, R. Bertuelli, M. Carletto, P.G. Casali, P. Beck-Peccoz, L. Fugazzola
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy : an Italian sarcoma group study
2012 G. Grignani, E. Palmerini, P. Dileo, S.D. Asaftei, L. D'Ambrosio, Y. Pignochino, M. Mercuri, P. Picci, F. Fagioli, P.G. Casali, S. Ferrari, M. Aglietta
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)
2020 I. Ray-Coquard, H. Hatcher, E. Bompas, A. Casado, A. Westermann, N. Isambert, P.G. Casali, S. Pratap, D. Stark, C. Valverde, A. Anand, M. Huizing, A. Floquet, L. Lindner, B. Hermes, B. Seddon, C. Coens, R. Jones, N. Reed
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
2012 A. Le Cesne, S. Cresta, R.G. Maki, J.Y. Blay, J. Verweij, A. Poveda, P.G. Casali, C. Balaña, P. Schöffski, F. Grosso, P. Lardelli, A. Nieto, V. Alfaro, G.D. Demetri
Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma
2017 V. Colia, M. Fiore, S. Provenzano, E. Fumagalli, R. Bertulli, C. Morosi, A.P. Dei Tos, M. Barisella, A. Gronchi, P.G. Casali, R. Sanfilippo
Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study
2019 S. Stacchiotti, N. Simeone, S. Lo Vullo, C. Morosi, F.G. Greco, A. Gronchi, M. Barisella, P. Collini, N. Zaffaroni, G.P. Dagrada, A.M. Frezza, L. Mariani, P.G. Casali
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma
2018 S. Stacchiotti, O. Mir, A. Le Cesne, B. Vincenzi, A. Fedenko, R.G. Maki, N. Somaiah, S. Patel, M. Brahmi, J.Y. Blay, K. Boye, K. Sundby Hall, H. Gelderblom, N. Hindi, J. Martin-Broto, H. Kosela, P. Rutkowski, A. Italiano, F. Duffaud, E. Kobayashi, P.G. Casali, S. Provenzano, A. Kawai
Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian rare cancer network
2020 S. Stacchiotti, N. Simeone, S. Lo Vullo, G.G. Baldi, A. Brunello, B. Vincenzi, E. Palassini, G. Dagrada, P. Collini, C. Morosi, F.G. Greco, M. Sbaraglia, A.P. Dei Tos, L. Mariani, A.M. Frezza, P.G. Casali
Activity of sunitinib in extraskeletal myxoid chondrosarcoma
2014 S. Stacchiotti, M.A. Pantaleo, A. Astolfi, G.P. Dagrada, T. Negri, A.P. Dei Tos, V. Indio, C. Morosi, A. Gronchi, C. Colombo, E. Conca, L. Toffolatti, M. Tazzari, F. Crippa, R. Maestro, S. Pilotti, P.G. Casali
Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
2014 M. Tazzari, T. Negri, F. Rini, B. Vergani, V. Huber, A. Villa, P. Dagrada, C. Colombo, M. Fiore, A. Gronchi, S. Stacchiotti, P.G. Casali, S. Pilotti, L. Rivoltini, C. Castelli
Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment
2017 M. Tazzari, V. Indio, B. Vergani, L. De Cecco, F. Rini, T. Negri, C. Camisaschi, M. Fiore, S. Stacchiotti, G.P. Dagrada, P.G. Casali, A. Gronchi, A. Astolfi, M.A. Pantaleo, A. Villa, C. Lombardo, F. Arienti, S. Pilotti, L. Rivoltini, C. Castelli
Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors
2020 R. Sanfilippo, C. Fabbroni, G. Fucà, E. Fumagalli, C. Morosi, M. Sbaraglia, A. Gronchi, P. Collini, A.P. Dei Tos, P.G. Casali
Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre : Should Radiotherapy Still be a Standard?
2018 M. Fiore, S. Ford, D. Callegaro, C. Sangalli, C. Colombo, S. Radaelli, A.M. Frezza, S.L. Renne, P.G. Casali, A. Gronchi
Adjuvant chemotherapy for soft tissue sarcoma
2015 P.G. Casali
Adjuvant imatinib for GI stromal tumors : when and for how long?
2016 R.S. Benjamin, P.G. Casali
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
2022 B. Vincenzi, A. Napolitano, M. Fiocco, O. Mir, P. Rutkowski, J. Blay, P. Reichardt, H. Joensuu, E. Fumagalli, S. Gennatas, N. Hindi, M. Nannini, M. Spalato Ceruso, A. Italiano, G. Grignani, A. Brunello, S. Gasperoni, T. De Pas, G. Badalamenti, M.A. Pantaleo, W.J. van Houdt, N.S. Ijzerman, N. Steeghs, H. Gelderblom, I.M.E. Desar, J. Falkenhorst, M. Silletta, M. Sbaraglia, G. Tonini, J. Martin-Broto, P. Hohenberger, A. Le Cesne, R.L. Jones, A.P. Dei Tos, A. Gronchi, S. Bauer, P.G. Casali
Adjuvant therapy for high-risk soft tissue sarcoma in the adult
2013 A. Gronchi, P.G. Casali